-transparent.png){kind=logo}
The success of chemotherapy in patients with leukemia whose marrow appears to be replaced by leukemia cells must be due to the persistence of normal stem cells. In this normal population are the progenitors of the cells of the immune system. Natural killer (NK) cells originate in the bone marrow. On maturation and activation with interleukin 2 (IL-2) or other cytokines, NK cells develop cytotoxic activity against a variety of leukemic blasts, including those from patients with chronic myeloid leukemia (CML). In the past few years, bone marrow transplantation (BMT) and alpha-interferon (IFN-alpha) have proved to be the most promising therapies for the treatment of CML. In both these therapies, NK cells may play a prominent role. In this article, we discuss the antitumor/antileukemia activity of human NK cells, the presence of benign NK cell precursors in the different stages of CML, the role of NK cells in BMT and IFN-alpha treatment, and the potential therapeutic applications of NK cells in patients with hematologic malignancies.
L M Silla, and
T L Whiteside, and
E D Ball
January 2011,
Revista brasileira de hematologia e hemoterapia,
L M Silla, and
T L Whiteside, and
E D Ball
May 2019,
Oncology reports,
L M Silla, and
T L Whiteside, and
E D Ball
January 1995,
Cancer genetics and cytogenetics,
L M Silla, and
T L Whiteside, and
E D Ball
July 2006,
Expert review of clinical immunology,
L M Silla, and
T L Whiteside, and
E D Ball
January 1990,
Neoplasma,
L M Silla, and
T L Whiteside, and
E D Ball
November 1997,
Leukemia & lymphoma,
L M Silla, and
T L Whiteside, and
E D Ball
January 1990,
Cancer immunology, immunotherapy : CII,
L M Silla, and
T L Whiteside, and
E D Ball
April 2014,
Zhongguo shi yan xue ye xue za zhi,
L M Silla, and
T L Whiteside, and
E D Ball
February 2020,
Immunology and cell biology,
L M Silla, and
T L Whiteside, and
E D Ball
September 2013,
Cancer science,
